<DOC>
	<DOCNO>NCT00816283</DOCNO>
	<brief_summary>RATIONALE : Dasatinib vorinostat may stop growth cancer cell block enzymes need cell growth . Giving dasatinib together vorinostat may kill cancer cell . PURPOSE : This phase I trial study side effect best dose dasatinib give together vorinostat treat patient accelerated phase blastic phase chronic myelogenous leukemia acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Dasatinib Vorinostat Treating Patients With Accelerated Phase Blastic Phase Chronic Myelogenous Leukemia Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - To define maximum tolerate dose dasatinib vorinostat patient accelerate phase blastic phase chronic myelogenous leukemia Philadelphia chromosome-positive acute lymphoblastic leukemia . - To assess toxicity regimen patient . - To assess , preliminarily , efficacy regimen patient . Secondary - To perform correlative study relevant regimen . OUTLINE : This multicenter study . Patients receive oral dasatinib twice daily day 1-21 oral vorinostat twice daily day 1-14 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Patients undergo bone marrow aspiration blood sample collection periodically correlative laboratory study . Samples assess RT-PCR DNA damage response proapoptotic element ( GADD45 , FANC , FOXO3A ) ; cytogenetic analysis ; flow cytometry ; mutation analysis bcr-abl ; gene expression array analysis .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 follow hematologic malignancy : Chronic myelogenous leukemia meeting 1 follow criterion : In accelerated phase , define presence ≥ 1 following : At least 15 % &lt; 30 % blast peripheral blood and/or bone marrow At least 30 % blast plus promyelocytes peripheral blood bone marrow ( provide &lt; 30 % blast present bone marrow ) At least 20 % basophils peripheral blood Platelet count &lt; 100,000/mm³ ( unrelated therapy ) OR platelet count &gt; 100,000/mm³ unresponsive therapy Cytogenetic evidence clonal evolution Increasing spleen size increase WBC count unresponsive therapy In blastic phase ( blast crisis ) , define presence ≥ 1 following : At least 30 % blast peripheral blood and/or bone marrow Extramedullary infiltrate leukemic cell ( liver spleen involvement ) Philadelphia chromosomepositive acute lymphoblastic leukemia meeting follow criterion : Newly diagnose relapsed disease Previously treat chemotherapy , stem cell transplantation , tyrosine kinase inhibitor ( TKIs ) No active CNS involvement PATIENT CHARACTERISTICS : ECOG performance status 02 Total bilirubin &lt; 2.0 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN Serum sodium , potassium , magnesium , phosphate , calcium ≥ low limit normal Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ≥ 4 week discontinuation study drug Able take oral medication No active posttransplantationrelated infection ( e.g. , fungal viral infection ) No active acute graftversushost disease ( GVHD ) grade No chronic GVHD ( mild skin , oral , ocular GVHD require systemic immunosuppression ) No malignancy require radiotherapy systemic treatment within past 5 year No concurrent medical condition may increase risk toxicity , include pleural pericardial effusion grade No cardiac condition , include follow : Uncontrolled angina , congestive heart failure , myocardial infarction within past 6 month Diagnosed congenital long QT syndrome History clinically significant ventricular arrhythmia ( e.g. , ventricular tachycardia , ventricular fibrillation , Torsades de pointes ) Prolonged QTc interval ( i.e. , QTc &gt; 450 msec ) baseline EKG No hypokalemia hypomagnesemia correct prior dasatinib administration No history significant bleeding disorder unrelated cancer , include follow : Diagnosed congenital bleeding disorder ( e.g. , von Willebrand 's disease ) Acquired bleed disorder diagnose within past year ( e.g. , acquire antifactor VIII antibody ) Ongoing recent ( i.e. , within past 3 month ) significant gastrointestinal bleeding No prisoner individual compulsorily detain ( i.e. , involuntarily incarcerate ) treatment either psychiatric physical ( e.g. , infectious ) illness PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior therapy No prior HDAC inhibitor compound HDAC inhibitorlike activity ( e.g. , valproic acid ) antitumor therapy Prior valproic acid treatment seizures allow provide give within past 30 day Prior allogeneic stem cell transplantation allow More 4 week since prior chemotherapy TKI ( 6 week nitrosoureas mitomycin ) More 2 week since prior radiotherapy At least 7 day since prior concurrent Category I drug generally accept risk cause Torsades de pointes , include follow : Quinidine , procainamide , disopyramide Amiodarone , sotalol , ibutilide , dofetilide Erythromycin clarithromycin Chlorpromazine , haloperidol , mesoridazine , thioridazine , pimozide Cisapride , bepridil , droperidol , methadone , arsenic , chloroquine , domperidone , halofantrine , levomethadyl , pentamidine , sparfloxacin , lidoflazine At least 7 day since prior concurrent medication directly durably inhibit platelet function , include follow : Aspirin aspirincontaining combination , clopidogrel , dipyridamole Tirofiban , epoprostenol , eptifibatide , cilostazol , abciximab , ticlopidine , cilostazol At least 5 day since prior concurrent St. John 's wort No IV bisphosphonates first 8 week dasatinib therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>Philadelphia chromosome positive adult precursor acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
</DOC>